Biomarkers in Breast Cancer

ISBN-13: 9781617374364 / Angielski / Miękka / 2010 / 342 str.

Giampietro Gasparini; Daniel F. Hayes

Opis

Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.

Spis treści

Part I. General Topics Guidelines for the Design of Clinical Studies for the Development and Validation of Therapeutically Relevant Biomarkers and Biomarker-Based Classification Systems Richard M. Simon Analytical Aspects of Biomarker Immunoassays in Cancer Research Fred C. G. J. Sweep, Chris M. G. Thomas, and Manfred Schmitt Tissue Microarrays: State of the Art, Pitfalls, and Promises Chungyeul Kim and Soonmyung Paik Part II. Assays for Gene Expression and Post-Translational Protein Abnormalities Gene Expression Profiling with DNA Microarrays: Revolutionary Tools to Help Diagnosis, Prognosis, Treatment Guidance, and Drug Discovery Michele De Bortoli and Nicoletta Biglia Part III. Assays for DNA Abnormalities Assays for Gene Amplification: State of the Art, Pitfalls, and Promises Chungyeul Kim, Yongkuk Song, and Soonmyung Paik Part IV. Tissue Predictive Biomarkers Cell Kinetics Maria Grazia Daidone, Rosella Silvestrini, and Dino Amadori Urokinase-Type Plasminogen Activator and PAI-1: Validated Prognostic Factors for Breast Cancer Michael J. Duffy Predictive Value of c-erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer Vered Stearns erb-B2 as a Therapeutic Target Robert Mass The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer Fortunato Ciardiello, Teresa Troiani, and Giampaolo Tortora p53 as a Prognostic and Predictive Indicator Daniela Kandioler and Raimund Jakesz Part V. Predictive Biomarkers in Body Fluids Occult Metastatic Cells in Breast Cancer Patients: State of the Art, Pitfalls, and Promises Stephan Braun, Julia Seeber, and Christian Marth Circulating HER2/neu: Clinical Utility Allan Lipton, Laurence Demers, Kim Leitzel, Suhail M. Ali, Rainer Neumann, Christopher P. Price, and Walter P. Carney Circulating Vascular Endothelial Growth Factor: Methods, Prognostic Significance, and Potential Application for Antiangiogenic Therapy Roberta Sarmiento, Roberta Franceschini, Sabrina Meo, Massimo Gion, Raffele Longo, and Giampietro Gasparini Detection of Early Tumor Dissemination in Patients with Breast Cancer Debra Hawes and Richard J. Cote Part VI. Future Directions New Technologies/New Markers/New Challenges Daniel F. Hayes and Giampietro Gasparini Index

Blurb

It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy.